Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

William D Tap

Alliance for Clinical Trials in Oncology

Intervention

Pazopanib(drug)

Enrollment

151 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2022

Study locations (30)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
• PCR Oncology, Arroyo Grande, California, United States
• Sutter Auburn Faith Hospital, Auburn, California, United States
• Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Pleomorphic undifferentiated sarcoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07049848
  SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT05813327
  Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
  Washington University School of Medicine
• ACTIVE NOT RECRUITINGNANCT05776667
  Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
  Medical University of South Carolina
• RECRUITINGNANCT05944913
  Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy
  Centre Leon Berard
• RECRUITINGPHASE3NCT05597917
  tTF-NGR Randomized Study - STS
  Universität Münster
• RECRUITINGNANCT04946357
  Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions
  University Hospital Heidelberg

See all trials for OBSOLETE: Pleomorphic undifferentiated sarcoma →